Home › Funds › Theleme Partners LLP › MRNA

Theleme Partners LLP position in MRNA

MODERNA INC · Health Care

Theleme Partners LLP reported holding 6,657,441 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$1.28B, representing 48.90% of its reported portfolio and ranking #1 among its reported holdings. Theleme Partners LLP has disclosed MRNA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)6.66M sh
Reported value held$1.28B
Portfolio Weight48.90%
First reportedQ3 2023
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Theleme Partners LLP's MRNA position evolved

Theleme Partners LLP first disclosed a stake in MRNA in Q3 2023 at 6,897,612 shares (US$712.5M). The position peaked in Q3 2026 at 6,657,441 shares, worth US$1.28B. Across 13 filings, Theleme Partners LLP increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 6,657,441 shares valued at US$1.28B — a reduction of -1,400,130 shares quarter over quarter.. Notable position changes include a 71% trim in Q4 2023 (shares rose 7% over the following quarter), a 100% trim in Q2 2024 (shares fell 44% over the following quarter), a 91557% increase in Q4 2024 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 6.90M $712.45M New
Q4 2023 2.01M $200.29M Reduce
Q1 2024 1.44M $153.45M Reduce
Q2 2024 6.20K $73.69M Reduce
Q3 2024 7.97K $53.28M Add
Q4 2024 7.31M $303.82M Add
Q1 2025 7.24M $205.32M Reduce
Q2 2025 7.87M $217.10M Add
Q3 2025 8.07M $208.42M Add
Q4 2025 8.08M $238.33M Hold
Q1 2026 8.05M $408.85M Hold
Q2 2026 8.06M $564.27M Hold
Q3 2026 6.66M $1.28B Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MRNA and 13F data

MRNA (MODERNA INC) is a Health Care company. 41 other funds we track also report a position in MRNA — the largest reported positions include Fidelity Management & Research (FMR) (US$11.35B), Capital World Investors (US$4.36B), Baillie Gifford & Co (US$2.20B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MRNA

All MRNA fund holders →

FAQ

How long has Theleme Partners LLP held MRNA?

Theleme Partners LLP has disclosed MRNA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Theleme Partners LLP's current position in MRNA?

As of Q3 2026, Theleme Partners LLP holds 6.66M shares of MRNA (MODERNA INC), valued at $1.28B, representing 48.90% of its reported portfolio and ranking #1.

Has Theleme Partners LLP been buying or selling MRNA?

In the latest 13F filing (Q3 2026), Theleme Partners LLP reduced its position in MRNA. The position peaked in Q3 2026 at 6.66M shares.

Which other funds hold MRNA?

Other major institutional holders of MRNA include Fidelity Management & Research (FMR), Capital World Investors, Baillie Gifford & Co, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.